公开(公告)号：US20150218279A1

公开(公告)日：2015-08-06

申请号：US14692948

申请日：2015-04-22

申请人： Pfizer Inc. ,  Bristol-Myers Squibb Company

发明人： Jing Min ,  Yanli Wu ,  Rory F. Finn ,  Barrett R. Thiele ,  Wei Liao ,  Ronald P. Gladue ,  Arvind Rajpal ,  Timothy J. Paradis ,  Peter Brams ,  Brigitte Devaux ,  Yi Wu ,  Kristopher Toy ,  Heidi N. LeBlanc ,  Haichun Huang

IPC分类号： C07K16/28

CPC分类号： C07K16/2878 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/92

摘要： The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

摘要翻译： 本公开提供了结合人OX40R的分离的结合分子，编码结合分子的氨基酸序列的核酸分子，包含核酸分子的载体，含有载体的宿主细胞，制备结合分子的方法，含有 结合分子，以及使用结合分子或组合物的方法。

公开(公告)号：US10196452B2

公开(公告)日：2019-02-05

申请号：US15807351

申请日：2017-11-08

申请人： Pfizer Inc. ,  Bristol-Myers Squibb Company

发明人： Jing Min ,  Yanli Wu ,  Rory F. Finn ,  Barrett R. Thiele ,  Wei Liao ,  Ronald P. Gladue ,  Arvind Rajpal ,  Timothy J. Paradis ,  Peter Brams ,  Brigitte Devaux ,  Yi Wu ,  Kristopher Toy ,  Heidi N. Leblanc ,  Haichun Huang

IPC分类号： C07K16/28 ,  A61K39/00

摘要： The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

公开(公告)号：US09840562B2

公开(公告)日：2017-12-12

申请号：US14692948

申请日：2015-04-22

申请人： Pfizer Inc. ,  Bristol-Myers Squibb Company

发明人： Jing Min ,  Yanli Wu ,  Rory F. Finn ,  Barrett R. Thiele ,  Wei Liao ,  Ronald P. Gladue ,  Arvind Rajpal ,  Timothy J. Paradis ,  Peter Brams ,  Brigitte Devaux ,  Yi Wu ,  Kristopher Toy ,  Heidi N. LeBlanc ,  Haichun Huang

IPC分类号： C07K16/28 ,  A61K39/00

CPC分类号： C07K16/2878 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/92

摘要： The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

公开(公告)号：US20180057600A1

公开(公告)日：2018-03-01

申请号：US15807351

申请日：2017-11-08

申请人： Pflzer Inc. ,  Bristol-Myers Squibb Company

发明人： Jing MIN ,  Yanli Wu ,  Rory F. Finn ,  Barrett R. Thiele ,  Wei Liao ,  Ronald P. Gladue ,  Arvind Rajpal ,  Timothy J. Paradis ,  Peter Brams ,  Brigitte Devaux ,  Yi Wu ,  Kristopher Toy ,  Heidi N. Leblanc ,  Haichun Huang

IPC分类号： C07K16/28

CPC分类号： C07K16/2878 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/92

摘要： The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

公开(公告)号：US20160152713A1

公开(公告)日：2016-06-02

申请号：US14820040

申请日：2015-08-06

申请人： Amgen Fremont Inc. ,  Pfizer Inc.

发明人： Vahe Bedian ,  Ronald P. Gladue ,  Jose Corvalan ,  Xiao-Chi Jia ,  Xiao Feng

IPC分类号： C07K16/28 ,  A61N5/10 ,  A61N5/06 ,  A61K39/395 ,  A61K45/06

CPC分类号： C07K16/2866 ,  A01K2217/05 ,  A61K39/3955 ,  A61K45/06 ,  A61K48/00 ,  A61K2039/505 ,  A61N5/062 ,  A61N5/10 ,  C07K16/2878 ,  C07K16/40 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/92

摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.

公开(公告)号：US09238691B2

公开(公告)日：2016-01-19

申请号：US14244167

申请日：2014-04-03

申请人： Pfizer Inc. ,  Amgen Fremont Inc.

发明人： Ronald P. Gladue ,  Bradley T. Keller ,  Shinji Ogawa ,  Arvind Rajpal ,  Laurie A. Tylaska ,  Shelley Sims Belouski ,  Larry L. Green ,  Meina Liang

IPC分类号： C07K16/28 ,  A61K39/00

CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92

摘要： Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, preferably human CCR2, and that may inhibit CCR2. The present antibodies may bind to the first and/or second extracellular loops of CCR2. Isolated heavy and light chains derived from the antibodies and nucleic acid molecules encoding the antibodies and chains are provided. Methods of making and using the anti-CCR2 antibodies or antigen-binding portions, and compositions comprising these antibodies or antigen-binding portions, including compositions for diagnosis and treatment, are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light chains that comprise the human anti-CCR2 antibodies or antigen-binding portions thereof.

摘要翻译： 提供了包括特异性结合CCR2，优选人CCR2的人抗体和其抗原结合部分的抗体，并且可以抑制CCR2。 本抗体可以结合CCR2的第一和/或第二细胞外环。 提供衍生自抗体的分离的重链和轻链以及编码抗体和链的核酸分子。 提供制备和使用抗CCR2抗体或抗原结合部分的方法，以及包含这些抗体或抗原结合部分的组合物，包括用于诊断和治疗的组合物。 还提供了使用编码包含人抗CCR2抗体或其抗原结合部分的重链和/或轻链的核酸分子的基因治疗方法。

公开(公告)号：US20140342450A1

公开(公告)日：2014-11-20

申请号：US14244167

申请日：2014-04-03

申请人： Amgen Fremont Inc. ,  Pfizer Inc.

发明人： Ronald P. Gladue ,  Bradley T. Keller ,  Shinji Ogawa ,  Arvind Rajpal ,  Laurie A. Tylaska ,  Shelley Sims Belouski ,  Larry L. Green ,  Meina L. Liang

IPC分类号： C07K16/28

CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92

摘要： Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, preferably human CCR2, and that may inhibit CCR2. The present antibodies may bind to the first and/or second extracellular loops of CCR2. Isolated heavy and light chains derived from the antibodies and nucleic acid molecules encoding the antibodies and chains are provided. Methods of making and using the anti-CCR2 antibodies or antigen-binding portions, and compositions comprising these antibodies or antigen-binding portions, including compositions for diagnosis and treatment, are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light chains that comprise the human anti-CCR2 antibodies or antigen-binding portions thereof.

摘要翻译： 提供了包括特异性结合CCR2，优选人CCR2的人抗体和其抗原结合部分的抗体，并且可以抑制CCR2。 本抗体可以结合CCR2的第一和/或第二细胞外环。 提供衍生自抗体的分离的重链和轻链以及编码抗体和链的核酸分子。 提供制备和使用抗CCR2抗体或抗原结合部分的方法，以及包含这些抗体或抗原结合部分的组合物，包括用于诊断和治疗的组合物。 还提供了使用编码包含人抗CCR2抗体或其抗原结合部分的重链和/或轻链的核酸分子的基因治疗方法。